Skip to main content
Cardiolucent

Service

Cardiovascular Care in Chronic Disease

Cardiovascular evaluation and optimization in the setting of underlying chronic disease — metabolic, inflammatory, oncologic, autoimmune — where the heart's risk profile and treatment plan are shaped by what else is happening in the body.

Why a separate service

Cardiovascular risk doesn't live in isolation.

The textbook cardiovascular risk calculators were built around age, blood pressure, cholesterol, smoking, and diabetes. They don't account for inflammatory rheumatic disease, prior chest radiation or anthracycline exposure, immunosuppression after transplant, immunotherapy for cancer, chronic kidney disease, HIV, or any of the other chronic conditions that meaningfully accelerate atherosclerosis, alter arrhythmia risk, or constrain which cardiovascular treatments are safe.

Cardiovascular Care in Chronic Disease is the service for patients whose cardiac care has to be calibrated against an active second or third diagnosis — where the right answer for a healthy 60-year-old is the wrong answer for them.

Metabolic, inflammatory, oncologic, autoimmune.

Common scenarios where the cardiovascular plan has to be designed around the underlying condition:

  • Metabolic. Diabetes, obesity, insulin resistance, fatty liver disease — drivers of accelerated atherosclerosis and arrhythmia substrate that need integrated metabolic + cardiovascular management.
  • Inflammatory. Rheumatoid arthritis, lupus, psoriatic disease, IBD — systemic inflammation independently raises cardiovascular risk; the cardiology workup and prevention strategy adjust accordingly.
  • Oncologic. Cardiotoxicity surveillance during and after cancer therapy (anthracyclines, HER2 agents, immune checkpoint inhibitors, radiation to the chest), and survivorship-stage cardiovascular care.
  • Autoimmune / transplant / chronic infection. Long-term immunosuppression, post-transplant care, HIV-associated cardiovascular risk — settings where standard guideline regimens may need modification.
  • Chronic kidney disease. Drug selection, anticoagulation strategy, and risk stratification all shift with reduced kidney function.

Coordinated with your other physicians, not in parallel.

When chronic disease shapes the cardiac picture, the cardiologist can't operate in a silo. Dr. Kedan communicates directly with your rheumatologist, oncologist, nephrologist, endocrinologist, transplant team, or infectious-disease physician so the medication regimen, surveillance imaging cadence, and risk-reduction strategy are all calibrated as one plan. The point isn't to add another cardiologist's opinion to the pile — it's to integrate cardiovascular care into what's already happening for you.

Common Questions

Frequently Asked Questions

I already see a specialist for [rheumatology / oncology / nephrology]. Why add a cardiologist?
Most subspecialists are excellent at their own area but don't have the time or the cardiology expertise to integrate cardiovascular risk into your overall plan. A cardiologist who understands your other conditions can adjust prevention strategy, choose medications that don't conflict, monitor for treatment-related cardiac effects, and intervene early when the risk picture shifts — without you having to translate between specialists.
Do you handle cardio-oncology specifically?
Yes, for the surveillance + management side. Cardiolucent provides cardiotoxicity monitoring during cancer treatment (serial echo with strain imaging, biomarkers, symptom assessment), evidence-based cardioprotective medication when warranted, and survivorship-stage cardiovascular care for years after treatment ends. For advanced or research-stage cardio-oncology needs, Dr. Kedan coordinates with dedicated cardio-oncology programs at major centers.
I take immunosuppressants — does that change my cardiology plan?
Yes, in several ways. Some immunosuppressants have direct cardiovascular effects (hypertension, lipid changes, arrhythmia risk). Some interact with cardiac medications. Long-term immunosuppression accelerates atherosclerosis independent of traditional risk factors. The cardiac evaluation and prevention plan should be calibrated around this — Dr. Kedan does that calibration explicitly rather than treating you as a baseline-risk patient.
I have stage 3 CKD. Will my cardiac medications need adjustment?
Often yes. Renal function affects drug dosing, anticoagulant choice, contrast-imaging decisions, and the risk-benefit of many cardiovascular interventions. Dr. Kedan integrates your kidney function into every medication and procedure decision and coordinates directly with your nephrologist where the plans intersect.
Will this replace my visits to my other specialists?
No. Cardiolucent provides the cardiovascular layer of your care and coordinates with your other physicians — it doesn't substitute for them. The goal is integration, not duplication.

Talk to Dr. Kedan about your situation.

Schedule a consultation at Cardiolucent in Beverly Hills.

Medical Disclaimer

The information on this site is for general educational purposes only and is not medical advice, diagnosis, or treatment. Reading this site does not create a doctor–patient relationship. Always consult a qualified healthcare professional for personal guidance. If this is an emergency, call 911. Mentions of medications, devices, or procedures are informational and not endorsements. Full medical disclaimer.

Some listed indications involve investigational/off-label use. Learn more.